hwagryul.com

Precision in every compound.

97.4 Therapeutic Efficacy Rate (%)
0 Compounds Analyzed
0 Active Trials
0 Approved Therapies

Pharmaceutical Analysis

Compound Efficacy Overview

Absorption Rate 94.2%
Bioavailability Index 0.87
Half-Life Duration 4.6h
Peak Plasma Concentration 128 ng/mL

Therapeutic Response Metrics

Primary Endpoint Achievement 91.7%
Secondary Endpoint Rate 84.3%
Adverse Event Incidence 2.1%
Patient Compliance Rate 96.8%

Clinical Monitoring

Safety Profile Analysis

Hepatotoxicity Risk Low (0.3%)
Renal Clearance Rate 72.4 mL/min
Drug Interaction Index Class A
Therapeutic Window 2.4 - 8.1 mg/L

Dosage Optimization

Recommended Starting Dose 50 mg
Maximum Tolerated Dose 200 mg
Dose-Response Linearity R² = 0.94
Steady-State Attainment Day 5

Population Pharmacokinetics

Volume of Distribution 68.2 L
Protein Binding 92.4%
Metabolic Pathway CYP3A4
Excretion Route Renal (67%)

Compound Registry

Compound Rate Phase Status
HGR-1047 97.4% Phase III Approved
HGR-2183 91.2% Phase III Approved
HGR-3291 88.6% Phase II Pending
HGR-4052 94.8% Phase III Approved
HGR-5178 79.3% Phase II Pending
HGR-6234 96.1% Phase III Approved
HGR-7389 83.7% Phase I Pending
HGR-8041 92.5% Phase III Approved
5 Approved
3 Pending
90.5% Avg. Rate